Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 17, 2020

View Archived Issues

Recruitment of miR-8080 by luteolin as new therapeutic strategy in CRPC

Pancreatitis protein promotes pain

Rett gene affects maternal behavior via cortical plasticity

Norepinephrine is "unexpected connection" between amyloid and tau

BioTheryX initiates dosing in first-in-human phase I study of BTX-A51

LAM-002 shows antitumor activity in clinical setting and is to be evaluated as treatment of ALS

Medshine Discovery identifies isocitrate dehydrogenase mutant inhibitors

New liver X receptor alpha and beta inverse agonists discovered at Phenex-FXR

Roche, ETHZ disclose new cannabinoid CB2 receptor ligands

Adenosine A2A receptor antagonists identified at Zhejiang Vimgreen Pharma

ViiV Healthcare UK patents HIV integrase inhibitors

CADM1v8/9 variant useful to detect SCLC

Oncogenic FHL2-GLI2 fusion identified in sclerosing stromal tumors of the ovary

Evidence of activity seen in phase I trial of RMC-4630 in KRAS-mutant non-small cell lung cancer

Long-term safety and efficacy of AAV5-hFVIII-SQ gene therapy

Two new combination substudies evaluate pembrolizumab for NSCLC

PGAM1 inhibitor HKB-99 reduces non-small cell lung cancer tumor growth in vivo

Researchers discover compound with potential for EZH2-driven cancers

FDA approves Ozempic to reduce MACE in adults with type 2 diabetes and heart disease

Amgen studies AMG-199 in patients with MUC17-positive gastric and GEJ cancer

Clene opens phase II study of CNM-Au8 in ALS

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...